KEYNOTE-365 in mCRPC Results

KEYNOTE-365 in mCRPC Results

obr

1 year
164 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai explains the results of KEYNOTe-365, pembrolizumab in metastatic castration-resistant prostate cancer (mCRPC).
Up Next Autoplay